Vitamin d and Application site reaction - a phase IV clinical study of FDA data

Summary:

Application site reaction is reported as a side effect among people who take Vitamin d (ergocalciferol), especially for people who are female, 60+ old, also take Vitamin C, and have Stress and anxiety.

The phase IV clinical study analyzes which people have Application site reaction when taking Vitamin d. It is created by eHealthMe based on reports of 282,675 people who have side effects when taking Vitamin d from the FDA, and is updated regularly.

What is Vitamin d?

Vitamin d has active ingredients of ergocalciferol. It is often used in low vitamin d. eHealthMe is studying from 294,094 Vitamin d users. Check the latest studies of Vitamin d.

What is Application site reaction?

Application site reaction is found to be associated with 387 drugs and 548 conditions by eHealthMe. Check the latest studies of Application site reaction.

On Jul, 11, 2026

282,675 people reported to have side effects when taking Vitamin d.
Among them, 35 people (0.01%) have Application site reaction.

Could Vitamin d cause Application site reaction?

Among these 35 people:

What is the gender of people who have Application site reaction when taking Vitamin d? *

female: 80 %
male: 20 %

What is the age of people who have Application site reaction when taking Vitamin d? *

What are other drugs people take besides Vitamin d? *

What are other side effects people have besides Application site reaction? *

Application Site Erythema (redness of the skin at application site): 7 people, 20.00%
Application Site Pruritus (application site severe itching of the skin): 7 people, 20.00%
Rashes (redness): 6 people, 17.14%
Headache (pain in head): 4 people, 11.43%
Itching: 3 people, 8.57%
Pain: 3 people, 8.57%
Application Site Rash: 3 people, 8.57%
Pollakiuria (abnormally frequent passage of relatively small quantities or urine): 3 people, 8.57%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 8.57%
Skin Exfoliation (removal of the oldest dead skin cells): 3 people, 8.57%

What are the existing conditions these people have? *

Stress And Anxiety: 4 people, 11.43%
Arthritis (form of joint disorder that involves inflammation of one or more joints): 3 people, 8.57%
Depression: 3 people, 8.57%
Psoriasis (immune-mediated disease that affects the skin): 3 people, 8.57%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 8.57%
Immunodeficiency Common Variable: 2 people, 5.71%
Multiple Allergies (allergy to multiple agents): 2 people, 5.71%
Breakthrough Pain: 2 people, 5.71%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 5.71%
Herpes Virus Infection: 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Vitamin d and have Application site reaction?

- Check whether Application site reaction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vitamin d:

Vitamin d (294,094 reports)

Browse all side effects of Vitamin d:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site reaction:

Application site reaction (387 drugs)

Browse all the conditions that are associated with Application site reaction:

Application site reaction (548 conditions)

Related publications that referenced our studies

Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .
Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .

How the study uses the data?

The study uses data from the FDA. It is based on ergocalciferol (the active ingredients of Vitamin d) and Vitamin d (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.